Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy (2024)
Sequence: WEARLARALARALARHLARALARALRACEA
| Experiment Id | EXP002463 |
|---|---|
| Paper | Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy |
| Peptide | RALA |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Set by N/P ratio; exact mass/µM not reported |
| Rna Concentration | 2.5 µg mRNA complexed with RALA for DC loading (ex vivo) |
| Mixing Ratio | N/P = 10 (RALA:mRNA) |
| Formulation Format | Ex vivo DC loading (control mCherry-mRNA/RALA) → DC vaccine (control) |
| Formulation Components | RALA + mCherry mRNA polyplex; bone-marrow-derived DCs; GM-CSF/IL-4; LPS maturation |
| Size Nm | |
| Zeta Mv | 26.20 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | Primary bone-marrow-derived DCs (C57BL/6) used as vaccine cells |
| Animal Model | C57BL/6 male mice with MC38 subcutaneous tumors |
| Administration Route | Subcutaneous injections of DC vaccine on days 7, 14, 21 post tumor inoculation (± adoptive TIL) |
| Output Type | Antitumor efficacy (tumor growth/weight) vs controls |
| Output Value | No significant tumor inhibition for non-neoantigen mRNA/DC vaccine vs PBS/TIL alone (qualitative in main text) |
| Output Units | |
| Output Notes | Used as non-neoantigen control; neoantigen vaccine showed stronger tumor inhibition and T cell responses |
| Toxicity Notes | No major toxicity discussed for this control vaccine |
| Curation Notes |